

A comparative study of the efficacy and safety of Monoclonal Anti-Rh (D) Immunoglobulin with Polyclonal Anti-Rh (D) Immunoglobulin for the Prevention of Maternal Rh-Isoimmunization.

¹Malvika Kumud, Associate Professor & Unit Head, Department of Obstetrics and Gynaecology, GMC, Bettiah.

²Richa Priyamvada, Senior Resident, Department of Obstetrics and Gynaecology, GMC, Bettiah.

³Shweta Rani, Specialist Medical Officer, Department of Obstetrics and Gynaecology, GMC, Bettiah.

Corresponding Author: Malvika Kumud, Associate Professor & Unit Head, Department of Obstetrics and Gynaecology, GMC, Bettiah.

Citation this Article: Malvika Kumud, Richa Priyamvada, Shweta Rani, “A comparative study of the efficacy and safety of Monoclonal Anti-Rh (D) Immunoglobulin with Polyclonal Anti-Rh (D) Immunoglobulin for the Prevention of Maternal Rh-Isoimmunization”, IJMSIR- April - 2022, Vol – 7, Issue - 2, P. No. 293 – 299.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Objectives: To compare the efficacy and safety of monoclonal anti-Rhesus (anti-D) immunoglobulin (IgG) with polyclonal anti-D IgG in the prevention of maternal Rh-isoimmunization.

Methods: This was a randomized, open-label, comparative clinical trial conducted in the obstetric in-patient department of Government Medical College, Bettiah, West Champ Aran (Bihar). 154 Rhesus (D)-negative women, not sensitized to Rh antigen and delivering Rh positive babies, received postpartum intramuscular administration of monoclonal or polyclonal anti-D IgG. The main outcome measures were the proportion of subjects protected from Rh-isoimmunization, identified by a negative indirect Coombs test (ICT) result, at day 180 after anti-D IgG administration, and incidence of adverse events.

Results: 78 subjects were randomized to the monoclonal group and 76 to the polyclonal group. 69 from the monoclonal group had a negative ICT result and none had a positive ICT result at day 180, whereas 68 from the

polyclonal group had a negative ICT result and one had a positive ICT result; the rest (9 and 7 subjects respectively) were lost to follow-up. A total of 3 adverse events were reported (2 in the monoclonal group and 1 in the polyclonal group); only one of these was serious. All the adverse events were judged to be unrelated to the interventional drug. None of the subjects in the monoclonal group developed immunogenic reaction to the monoclonal anti-D.

Conclusion: The efficacy and safety of the monoclonal preparation of anti-D was comparable to the polyclonal preparation of anti-D when used in the prevention of maternal Rh-isoimmunization.

Keywords: Rhesus, Immunoglobulin, Monoclonal, Isoimmunization, Polyclonal.

Introduction

The clinical practice of passive immunization of Rhesus (Rh) negative pregnant women with anti-Rh immunoglobulin (IgG) for the prevention of sensitization to the Rh (D) antigen began in the 1960s, when multiple studies reported about its effectiveness and possible

mechanisms of action. The most important sensitizing event for Rh-negative women occurs at the end of the pregnancy, with detachment of the placenta during delivery. Prophylaxis with anti-D IgG induces a strong immunosuppressive effect, although its exact mechanism is not fully understood. The proposed mechanisms include accelerated clearance of Rh-positive cells, epitope masking, inhibition due to antibodies against Fcγ RIIB or anti-idiotypic, inhibition of immature dendritic cells, and inhibition of B-cell clones specific for the Rh antigen. Accelerated destruction of Rh-positive red blood cells is the most widely accepted main mechanism of action. The incidence of postpartum anti-D sensitization has reduced from 13-19 to 0.9-1.8% with postpartum immunoprophylaxis and further to 0.1-0.3% with addition of antenatal immunoprophylaxis. With this high success rates, effectiveness over a period of 12 weeks and safe profile, anti-D IgG exemplifies a remarkable success story in the field of obstetrics and preventive care. Owing to these dramatic results with anti-D, systematic anti-D prophylaxis in all Rh-negative pregnant women was proposed in the 1970s and has become part of standard guidelines across the world.

The conventional polyclonal anti-D IgG is produced by fractionation of IgG from pooled plasma of donors who are mostly men, deliberately immunized with Rh-positive red cells. The manufacture of polyclonal anti-D IgG is thus limited by the availability of suitable human plasma donors. Monoclonal anti-D IgG produced using hybridoma or recombinant DNA technologies overcome this limitation and provide a virtually unlimited supply of the antibody. The available monoclonal anti-D has been demonstrated to have similar physicochemical and biological properties to conventional polyclonal anti-D.

This study aimed to compare the efficacy and safety of this monoclonal anti-D preparation with that of conventional polyclonal anti-D when used for postpartum immunoprophylaxis.

Materials and Methods

Study Design

This was a randomized, controlled, trial comparing monoclonal anti-D preparation with conventional polyclonal anti-D preparation in the in-patient department of Government Medical College, Bettiah. The overall study was designed as per the European Medicines Agency “Guideline on the clinical investigation of human anti-D immunoglobulin for intravenous and/ or intramuscular use – CPMP/BPWG/575/99 Rev. 1”. The trial was conducted at obstetric in-patient departments of GMC, Bettiah, Bihar. The trial protocol was approved by the institutional ethics committee of GMCH. The trial was performed in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, and local regulatory requirements. All participants were explained about the study and need for follow up, and provided voluntary, written, informed consent.

Study Participants

Rh-negative pregnant women delivering a Rh-positive baby, with a negative ICT test result were eligible for the study. The main exclusion criteria were positive ICT test result at baseline, Rh-negative blood group of husband/partner, history of incompatible blood transfusion, history of allergic reaction to IgGs, anticipated requirement of blood transfusion after delivery and diagnosis of abruptio placentae, placenta previa or intrauterine death. The present study was envisaged as a study with two group 1:1 ratio with a

sample size of 77 subjects per group. Up to 1.8% of women develop anti-D antibodies despite post-natal anti-D administration.

Study Randomization

Women were randomly assigned in a 1:1 ratio, to either the monoclonal or polyclonal anti-D groups, using a computer-generated randomization code.

Intervention

The subjects received either monoclonal anti-D (Rho clone, Bharat Serums and Vaccines Ltd.) or polyclonal anti-D (RhoGAM, Johnson & Johnson) at a dose of 300 mcg, since a dose of 300 mcg (1500 IU) of anti-D IgG protects against 30 mL of whole blood and literature data report that the fetomaternal hemorrhage (FMH) exceeding 30 mL is exceedingly rare (0.2-0.3% pregnancies). Cases where investigators suspects FMH > 30 ml were not considered for the study.

Study Procedure

Each eligible subject received a single intramuscular injection of anti-D IgG within 72 hr of delivery. Blood samples were collected before study drug administration (baseline) and at 72 hr, 90 days and 180 days from the anti-D administration, as recommended by the European Medicines Agency guidelines. ICT was performed on all samples, while testing for anti-drug antibodies was performed on baseline, day 90 and day 180 samples. Adverse events were recorded throughout the study.

Study Outcomes


The primary efficacy variable was the proportion of subjects with a negative ICT result on day 180 following administration of anti-D. ICT is used to detect circulating antibodies to red cell antigens. A positive ICT result in a subject at day 180, who had negative ICT result before administration of anti-D would indicate that the subject got immunized to Rh antigen. ICT results at 72 h and

Day 90 were also assessed, however since anti-D IgG from administered anti-D injection is present in detectable quantities up to 12 weeks and since it is not possible to distinguish between administered and immune anti-D IgG, these results were considered as supportive evidence and were not carried forward for Day 180. Only serial rise in titers was considered as positive result.

The safety variables were incidence of adverse events, including the injection site reactions in both groups, and incidence of immunogenicity (development of anti-drug antibodies) in the monoclonal group.

Statistical Analysis

The results were analyzed to explore the non-inferiority of the monoclonal anti-D with polyclonal anti-D for the primary efficacy variable. The results were analyzed by using the P value.



* Since the difference between ITT and PP population was minor, only ITT analysis was performed.

Results

Baseline Characteristics

The trial was conducted between March 15, 2020 and March 31, 2022. A total of 170 women were screened, of whom 154 were randomized and received one of the study drugs: 78 received monoclonal anti-D and 76 received polyclonal anti-D. The trial and participant flow shown in fig. 1.

Demographics and baseline characteristics were comparable between the two treatment groups (Table-1)

	Monoclonal anti-D	Polyclonal anti-D
Subjects randomized (n)	78	76
Age (mean ± SD)	24.77	24.75
Type of delivery (n)		
Vaginal	56	50
LSCS	20	24
Forceps/Vacuum	2	2
Subjects who completed day 90 visit [n (%)]	75 (96.15%)	70 (89.5%)
Subjects who completed day 180 visit [n (%)]	70 (89.75%)	66 (89.8%)

SD standard deviation, LSCS lower segment caesarean section

The ITT/safety population included all 154 patients who received either of the study drugs and the per protocol (PP) population included 152 (98.7%) subjects. Two subjects enrolled into the study had a protocol deviation and hence were excluded from the PP population. However, since the difference between ITT and PP population was minor, only ITT analysis was performed. Out of 154 randomized subjects, 146 (94.8%) subjects completed day 90 visit whereas 137 (88.9%) subjects completed day 180 visit. One subject died during the study due to an event unrelated to the study. No subject

was discontinued due to safety reasons. Among the randomized subjects, 8 subjects of the monoclonal group and 9 subjects from polyclonal group were lost to follow up before study completion.

Efficacy Endpoints

At Day 90, 2 (2.6%) subjects from the polyclonal group and none from the monoclonal group had a positive ICT result. At Day 180, one subject from the polyclonal group and none from the monoclonal group had a positive ICT result. At Day 90, a negative ICT, indicating absence of Rh immunization was seen in 96.15% subjects in monoclonal group and 89.5% subjects in the polyclonal group.

In the ITT population, the primary efficacy parameter (negative ICT result) at day 180 after administration of anti-D was reported in 89.75% in the monoclonal group and 86.8% in the polyclonal group.

Table 2

Time-point and result	Monoclonal anti-D (n = 78)	Polyclonal anti-D (n = 76)
Day 90		
Positive	0	2
Negative	74	68
LTF	4	6
Day 180		
Positive	0	1
Negative	68	65
LTF	10	11

Calculated for ITT population with lost to follow-up patients considered as failure of therapy; LTF lost to follow-up.

This demonstrated almost similar efficacy between the monoclonal and polyclonal group i.e. both were comparable though monoclonal a better one.

Safety Outcomes

5 Adverse events were reported by 5 subjects, 3 subjects from the monoclonal anti-D group and 2 from the polyclonal anti-D group (Table-3). Out of the 3 AEs reported in the monoclonal group, two were mild and one was severe and both AEs reported in polyclonal group were mild. The severe AE reported in monoclonal group pertained to a 22-year old primigravida who was being medically managed for severe pre-eclampsia and severe oligohydramnios with intrauterine growth retardation. She subsequently underwent emergency growth retardation. She subsequently underwent emergency LSCS for fetal distress following which she received monoclonal anti-D IgG. However, two days later, she developed cerebral infarction and 8 days later succumbed, despite intensive care management. The event was considered unrelated to the study drug, but due to the concurrent illness. All other AEs resolved without any sequelae/complications. All the AEs were judged to be unrelated to the study drugs.

Adverse event	Monoclonal anti-D group	Polyclonal anti-D group
Anemia	0	2
Body ache	1	0
Itching	1	0
Cerebral Infarct	1	0

Outcome was death; unrelated to the study. All adverse events were judged to be unrelated to study treatment.

Immunogenicity

The immunogenicity testing (test to demonstrate generation of antibodies) in the monoclonal anti D group revealed that none of the subjects developed antibodies against monoclonal anti-D.

Discussions

The estimated worldwide prevalence of Rh disease is 276 per 1,00000 live births. The conventional polyclonal preparation of anti-D IgG, with its high success rate and safety profile has been the mainstay in the prevention of Rh disease for over 5 decades now. In recent times, however, the commercial availability of this IgG preparation has been affected, primarily due to limited availability of this hyper immune plasma. There now exists a worldwide shortage of polyclonal anti-D IgG, leading to an increased cost over the monoclonal anti-D, a situation not anticipated to improve. Additionally, there is increasing concern about the risk of transmission and newly emerging viruses, specially since in most countries all Rh negative pregnant women are offered anti-D antenatally, irrespective of the Rh status of the fetus.

Manufacturing monoclonal and recombinant anti-D antibodies using modern biotechnology methods started over 3 decades ago. These specific anti-D antibodies originate from human B cells and should be able to overcome the concerns with respect to safety and supply of anti-D. The technology makes it possible to avoid the need for human donors and human products. Thereby decreasing the risk of disease transmission, protein impurities and batch to batch inconsistencies. Many monoclonal and recombinant anti-D IgG have been developed and tested. Certain monoclonal anti-D preparations are currently being studied in early phases of clinical trials.

Rho clone is a preparation of human monoclonal anti-rhesus antibodies (IgG1 subclass) that is available in India since 2007 and is to date the only monoclonal anti-D marketed in the world. It is derived from a stable hetero-hybridoma cell line and purified using protein affinity chromatography. This is the only study to have

evaluated the application of monoclonal anti-D in a large number of women requiring anti-D in the clinical setting. The study did not evaluate anti-natal administration of anti-D as it would have impacted study conduct and analysis many of the enrolled subjects would have ended up with Rh negative baby, thus not being ideal candidates for efficacy assessment and ensuring that subjects enrolled in the anti-natal period return to the same study site for child-birth and receive the same anti-D brand would have been a challenge.

In this study, both monoclonal and polyclonal anti-D IgG preparations demonstrated effective protection in Rh negative women, against isoimmunization with Rh antigen from their Rh-positive babies. One patient in the polyclonal group was ICT positive. Despite of the use of post-natal prophylaxis, antibody formation occurs during pregnancy in about 1 to 2%.

Even with addition of antenatal prophylaxis, the rate of antibody formation is 0.2 to 0.3% but not 0%. Alternatively, the dosage could have been inadequate. The standard dose of 300 mcg for prophylaxis will protect 997/1000 women from isoimmunization; in case with fetomaternal haemorrhage, this dose could prove inadequate.

No specific adverse reactions related to either preparation was reported. In addition, the monoclonal anti-D preparation did not result in an immunogenic reaction in any subject. Coupled with the other advantages associated with monoclonal antibodies over polyclonal antibodies-better batch-to-batch consistency, lesser protein impurities, lesser risk of disease transmission and practically unlimited supply, monoclonal anti-D provides an attractive and viable alternative to the conventional polyclonal preparation.

Conclusion

In conclusion, the study demonstrated the two anti-D preparations are clinically similar, and the newer monoclonal anti-D preparation is a suitable alternative to the conventional polyclonal anti-D in the prevention of maternal isoimmunization.

Compliance with Ethical Standards

Ethics

The trial protocol was approved by the institutional ethics committee.

Informed Consent

Informed consent was obtained from all individual participants included in the study by the respective investigators.

References

1. Bolton-Mags PH, Davies T, Poles D, et al. Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential hemovigilance scheme. *BJOG Int J Obstet Gynaecol.* 2013; 120(7):873-8.
2. Kent J, Farrell AM, Soothill P. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. *BMC Pregnancy Childbirth.* 2014; 14(1):87.
3. Velkova E. Correlation between the amount of anti-D antibodies and IgG subclasses with severity of haemolytic disease of foetus and newborn. *Open Access Maced J Med Sci.* 2015; 3(2):293.
4. De Haas M, Thurik FFj, Van Der Ploeg CP, et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands, *BMJ.* 2016;7(355): i5789.

5. Prevention of Rh D alloimmunization. Practice Bulletin No. 181 American College of Obstetricians and Gynecologists. *Obs Gynecol.* 2017; 130: e57-70.
6. Reichert JM. Antibodies to watch in 2017. In: *MABs* 2017 Feb 17, vol 9, no. 2. Taylor & Francis. P. 167-81.
7. Costumbrado J, Ghassemzadeh S. Rh Incompatibility. [Updated 2017 Oct 16]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2018Jan. <https://www.ncbi.nlm.nih.gov/books/NBK459353/>
8. Rhoclone Pack Inset. [cited 2018 Mar 30]. [www.bharatserums.com/product/endoprost/RHOCLONE\(Liquid\)CommonPackInsertforDomestic.pdf](http://www.bharatserums.com/product/endoprost/RHOCLONE(Liquid)CommonPackInsertforDomestic.pdf).
9. A Multicenter, Randomized, Open-Label Trial Comparing the Efficacy and Safety of Monoclonal Anti-Rh (D) Immunoglobulin with Polyclonal Anti-Rh (D) Immunoglobulin for the Prevention of Maternal Rh-Isoimmunization/ *JOGI* (Sept-Oct 2019) 69(5):420-425.